Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Harbeck, N; Wrobel, D; Zaiss, M; Terhaag, J; Guth, D; Distelrath, A; Zahn, MO; Wuerstlein, R; Lorenz, A; Bartsch, R; Breitenstein, U; Schwitter, M; Balic, M; Jackisch, C; Mueller, V; Rinnerthaler, G; Schmidt, M; Zaman, K; Schinköthe, T; Resch, A; Valenti, R; Lüftner, D.
Neratinib as extended adjuvant treatment of HER2-positive/HR-positive early breast cancer patients in Germany, Austria and Switzerland: interim results of the prospective, observational ELEANOR study
BREAST CARE. 2023;
Doi: 10.1159/000533657
Web of Science
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Balic Marija
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Introduction: Prognosis of patients diagnosed with HER2+ early breast cancer (eBC) has substantially improved, but distant recurrences impacting quality of life and survival still occur. One treatment option for extended adjuvant treatment in patients with HER2+/HR+ eBC is neratinib; available in Europe for patients who completed adjuvant trastuzumab-based therapy within 1 year. The ELEANOR study is investigating the real-world use of neratinib in Germany, Austria and Switzerland. Results from an interim analysis of the first 200 patients observed for >= 3 months are reported.Methods: The primary objective of this prospective, multicentre, observational study is to assess patient adherence to neratinib (defined as percentage of patients taking neratinib on >= 75% prescribed days). Secondary objectives are patient characteristics and treatment outcomes.Results: At cut-off (May 2, 2022), 202 patients had been observed for >= 3 months, with neratinib treatment documented for 187 patients (median age 53.0 years; 67.9% at increased risk of disease recurrence). In total 151 (80.7%) patients had received prior neoadjuvant treatment; of these 82 (54.3%) achieved a pathological complete response. Neratinib was initiated at a median 3.6 months after trastuzumab-based treatment, with 36.4% starting at a dose <240 mg/day. Treatment is ongoing for 46.0% of patients, with median treatment duration of 11.2 (interquartile range 0.9-12.0) months. Diarrhoea was the most common adverse event (78.6% any grade, 20.3% Grade >= 3); pharmacologic prophylaxis was used in 85.6% of patients.Conclusions: The pattern of anti-HER2 pretreatment observed reflected the current treatment for HER2+/HR+ eBC in Germany, Austria and Switzerland. These interim results suggest that neratinib as an extended adjuvant is a feasible option after various anti-HER2 pretreatments, and that its tolerability can be managed and improved with proactive diarrhoea management.
- Find related publications in this database (Keywords)
- HER2-positive
- HR-positive
- early breast cancer
- extended adjuvant
- neratinib